Cargando…

The Role of Complement in HSCT-TMA: Basic Science to Clinical Practice

Hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA) is a common complication occurring post-HSCT and is associated with substantial morbidity and mortality if not promptly identified and treated. Emerging evidence suggests a central role for the complement system...

Descripción completa

Detalles Bibliográficos
Autores principales: Meri, Seppo, Bunjes, Donald, Cofiell, Roxanne, Jodele, Sonata
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9402756/
https://www.ncbi.nlm.nih.gov/pubmed/35781192
http://dx.doi.org/10.1007/s12325-022-02184-4
_version_ 1784773228734971904
author Meri, Seppo
Bunjes, Donald
Cofiell, Roxanne
Jodele, Sonata
author_facet Meri, Seppo
Bunjes, Donald
Cofiell, Roxanne
Jodele, Sonata
author_sort Meri, Seppo
collection PubMed
description Hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA) is a common complication occurring post-HSCT and is associated with substantial morbidity and mortality if not promptly identified and treated. Emerging evidence suggests a central role for the complement system in the pathogenesis of HSCT-TMA. The complement system has also been shown to interact with other pathways and processes including coagulation and inflammation, all of which are activated following HSCT. Three endothelial cell-damaging “hits” are required for HSCT-TMA genesis: a genetic predisposition or existing damage, an endothelial cell-damaging conditioning regimen, and additional damaging insults. Numerous risk factors for the development of HSCT-TMA have been identified (including primary diagnosis, graft type, and conditioning regimen) and validated lists of relatively simple diagnostic signs and symptoms exist, many utilizing routine clinical and laboratory assessments. Despite the relative ease with which HSCT-TMA can be screened for, it is often overlooked or masked by other common post-transplant conditions. Recent evidence that patients with HSCT-TMA may also concurrently present with these differential diagnoses only serve to further confound its identification and treatment. HSCT-TMA may be treated, or even prevented, by removing or ameliorating triggering “hits”, and recent studies have also shown substantial utility of complement-targeted therapies in this patient population. Further investigation into optimal management and treatment strategies is needed. Greater awareness of TMA post-HSCT is urgently needed to improve patient outcomes; the objective of this article is to clarify current understanding, explain underlying complement biology and provide simple tools to aid the early recognition, management, and monitoring of HSCT-TMA. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12325-022-02184-4.
format Online
Article
Text
id pubmed-9402756
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-94027562022-08-26 The Role of Complement in HSCT-TMA: Basic Science to Clinical Practice Meri, Seppo Bunjes, Donald Cofiell, Roxanne Jodele, Sonata Adv Ther Review Hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA) is a common complication occurring post-HSCT and is associated with substantial morbidity and mortality if not promptly identified and treated. Emerging evidence suggests a central role for the complement system in the pathogenesis of HSCT-TMA. The complement system has also been shown to interact with other pathways and processes including coagulation and inflammation, all of which are activated following HSCT. Three endothelial cell-damaging “hits” are required for HSCT-TMA genesis: a genetic predisposition or existing damage, an endothelial cell-damaging conditioning regimen, and additional damaging insults. Numerous risk factors for the development of HSCT-TMA have been identified (including primary diagnosis, graft type, and conditioning regimen) and validated lists of relatively simple diagnostic signs and symptoms exist, many utilizing routine clinical and laboratory assessments. Despite the relative ease with which HSCT-TMA can be screened for, it is often overlooked or masked by other common post-transplant conditions. Recent evidence that patients with HSCT-TMA may also concurrently present with these differential diagnoses only serve to further confound its identification and treatment. HSCT-TMA may be treated, or even prevented, by removing or ameliorating triggering “hits”, and recent studies have also shown substantial utility of complement-targeted therapies in this patient population. Further investigation into optimal management and treatment strategies is needed. Greater awareness of TMA post-HSCT is urgently needed to improve patient outcomes; the objective of this article is to clarify current understanding, explain underlying complement biology and provide simple tools to aid the early recognition, management, and monitoring of HSCT-TMA. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12325-022-02184-4. Springer Healthcare 2022-07-04 2022 /pmc/articles/PMC9402756/ /pubmed/35781192 http://dx.doi.org/10.1007/s12325-022-02184-4 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Review
Meri, Seppo
Bunjes, Donald
Cofiell, Roxanne
Jodele, Sonata
The Role of Complement in HSCT-TMA: Basic Science to Clinical Practice
title The Role of Complement in HSCT-TMA: Basic Science to Clinical Practice
title_full The Role of Complement in HSCT-TMA: Basic Science to Clinical Practice
title_fullStr The Role of Complement in HSCT-TMA: Basic Science to Clinical Practice
title_full_unstemmed The Role of Complement in HSCT-TMA: Basic Science to Clinical Practice
title_short The Role of Complement in HSCT-TMA: Basic Science to Clinical Practice
title_sort role of complement in hsct-tma: basic science to clinical practice
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9402756/
https://www.ncbi.nlm.nih.gov/pubmed/35781192
http://dx.doi.org/10.1007/s12325-022-02184-4
work_keys_str_mv AT meriseppo theroleofcomplementinhscttmabasicsciencetoclinicalpractice
AT bunjesdonald theroleofcomplementinhscttmabasicsciencetoclinicalpractice
AT cofiellroxanne theroleofcomplementinhscttmabasicsciencetoclinicalpractice
AT jodelesonata theroleofcomplementinhscttmabasicsciencetoclinicalpractice
AT meriseppo roleofcomplementinhscttmabasicsciencetoclinicalpractice
AT bunjesdonald roleofcomplementinhscttmabasicsciencetoclinicalpractice
AT cofiellroxanne roleofcomplementinhscttmabasicsciencetoclinicalpractice
AT jodelesonata roleofcomplementinhscttmabasicsciencetoclinicalpractice